查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2013102

脈絡膜萎縮症市場：全球產業分析、市場規模、市佔率及2026年至2033年預測（依治療方法、給藥途徑、病患細分、疾病階段、最終用戶、國家及地區分類）

Choroideremia Market, By Treatment Type, By Route of Administration, By Patient Demographics, By Disease Stage, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 304 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，脈絡膜萎縮市場價值將達到 97.8595 億美元，並預計從 2026 年到 2033 年將以 4.87% 的複合年成長率成長。

脈絡膜視網膜色素變性是一種罕見的遺傳性眼科疾病，主要影響男性，會導致視力逐漸喪失。此病初期表現為弱光視力下降，隨後逐漸發展為周邊視野喪失，最終發展為中心視野喪失，有時甚至會導致失明。根據美國國立衛生研究院 (NIH) 的政府數據，該疾病的發生率約為五萬至十萬分之一，並佔失明病例的一部分。脈絡膜視網膜色素變性市場指的是參與開發和銷售這種罕見眼科疾病治療方法（特別是基因療法等新型治療方法）的業務。儘管受影響的人數很少，但由於企業對研發的大量投入、新治療方法的開發以及對能夠真正延緩或阻止視力喪失的治療方法的迫切需求，該市場仍在持續擴張。

脈絡膜萎縮市場－市場動態

基因治療研發日益受到關注

脈絡膜視網膜色素變性市場的主要驅動力是基因療法研發的擴張，而政府的援助和監管激勵措施是推動這項擴張的關鍵。美國國立衛生研究院 (NIH) 透過資助和針對罕見疾病的舉措來推進基因療法項目，因為罕見疾病的治療選擇往往有限。由於脈絡膜視網膜色素變性是由單一基因突變引起的，因此非常適合基因替代療法，而政府支持的研究已經推動這些治療方法進入臨床試驗階段，為患者帶來了顯著的益處。百健公司 (Biogen Inc.)、Spark Therapeutics 和 REGENXBIO 公司等企業正在積極研發這些治療方法。此外，美國食品藥物管理局(FDA) 授予了孤兒藥資格認定和罕見疾病認定，幫助企業加速研發進程。這反過來又直接刺激了研究活動和市場成長。

脈絡膜視網膜色素變性市場－市場區隔分析：

全球脈絡膜視網膜萎縮市場按治療方法、給藥途徑、患者人口統計特徵、疾病進展階段、最終用戶和地區進行細分。

根據治療方法方式的不同，市場可細分為六個領域：基因療法、手術介入、藥物療法、症狀治療、細胞療法和藥物療法。基因療法在該市場中佔據最重要的地位，因為它能夠直接修復導致該疾病的CHM基因，而其他療法（例如藥物和手術）只能控制症狀，無法阻止視力喪失。這種疾病極為罕見，發生率約五萬分之一到十萬分之一，因此世界各國政府將其列為罕見疾病，並透過孤兒藥計畫和研究經費支持其研發。基因療法的獨特之處在於它利用病毒載體（例如AAV）將功能基因導入視網膜細胞，臨床試驗已證實部分患者的視力得以維持或改善。作為一種針對病因的一次性治療方法，基因療法已展現出顯著的臨床療效，因此獲得了大部分的資金、臨床試驗和監管關注，使其成為應用最廣泛的領域。

從給藥途徑來看，市場可分為四個領域：視網膜下注射、玻璃體內注射、口服和靜脈注射。視網膜下注射預計將在脈絡膜萎縮市場中發揮核心作用，因為它能將基因療法直接遞送至病變部位的受損視網膜細胞。政府支持的臨床研究表明，脈絡膜萎縮的基因療法主要透過視網膜下注射給藥，這已透過腺結合病毒（AAV）的療法臨床試驗得到證實，這些治療方法可直接靶向視網膜色素上皮和感光細胞。科學研究也證實，與其他給藥途徑相比，視網膜下注射能夠實現更精準、更有效的藥物遞送，從而使目標部位的藥物濃度更高。 Spark Therapeutics 和 REGENXBIO Inc. 等公司廣泛採用這種方法，這些公司專注於需要直接遞送至視網膜的基於 AAV 的療法。該療法的關鍵特點包括標靶基因遞送、提高治療效果以及適用於單劑量治療，儘管比玻璃體內注射等替代療法更具侵入性，但仍是應用最廣泛的治療途徑。

脈絡膜萎縮市場—區域分析

在北美，強大的研究基礎和政府對罕見疾病治療的持續支持預計將推動脈絡膜視網膜萎縮症市場顯著成長。美國國立衛生研究院 (NIH) 正在資助多個針對遺傳性視網膜疾病的基因治療項目，並為這些項目從早期研究到臨床試驗提供全程支持。同時，美國食品藥物管理局(FDA) 正在授予孤兒藥資格，以加速治療方法的研發。在美國，政府支持的研究，以及 Spark Therapeutics 和 REGENXBIO 等公司的參與，已經將脈絡膜視網膜萎縮症的基因治療推進到人體臨床試驗階段，並取得了可衡量的視力改善。歐洲是下一個關鍵地區，這得益於積極的臨床研究和公共醫療體系的參與。在英國，政府主導的臨床試驗，包括由英國衛生署資助的試驗，正在推動視網膜下基因治療的早期人體試驗，並且制定了系統性的罕見疾病政策，以支持正在進行的研究和患者獲得治療。

加拿大脈絡膜萎縮市場—國家概況

加拿大是脈絡膜視網膜色素變性（CRP）市場的重要國家，這得益於政府強力的研究支持以及對罕見眼科疾病的明確醫療保健重視。加拿大防​​盲協會等機構的數據顯示，加拿大約有21,000人患有遺傳性視網膜疾病，其中包括脈絡膜視網膜色素變性，這表明加拿大存在一個需要長期照護和治療的特殊患者群體。此外，加拿大政府支持的臨床研究表明，超過68%的此類患者在法律意義上屬於視覺障礙者，凸顯了沉重的醫療負擔以及對有效治療方法的迫切需求。加拿大在學術和臨床領域也擁有強大的實力，例如亞伯達大學等機構在CRP的基因研究和診斷方面做出了貢獻。致力於基因療法的公司和研究團隊透過公共醫療保健計劃以及與全球生物技術公司的合作獲得支持。總而言之，加拿大完善的醫療保健體系、持續的研究活動以及明確的患者群體為新治療方法的開發和推廣提供了穩定且有組織的支撐。

目錄

第1章：刺繡市場概覽

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：刺繡產業的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：脈絡膜繡術產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：刺繡市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：刺繡的市場狀況

  • 2025年脈絡膜繡市場佔有率分析
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章：脈絡膜萎縮症市場：依治療類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按治療類型
    • 基因治療
    • 手術介入
    • 藥物治療
    • 症狀治療
    • 細胞療法
    • 藥物治療

第8章：刺繡市場：依管理途徑分類

  • 概述
    • 按給藥途徑分類的市佔率分析
    • 視網膜下注射
    • 玻璃體內注射
    • 口服
    • 靜脈注射

第9章：氯異症市場：依患者群體細分

  • 概述
    • 細分市場佔有率分析：依患者屬性分類
    • 兒童患者
    • 成年患者
    • 老年患者

第10章：綠膿病市場：依疾病進展階段分類

  • 概述
    • 按給藥途徑分類的市佔率分析
    • 初期
    • 中期
    • 晚期

第11章：刺繡市場：依最終用戶分類

  • 概述
    • 基於細分市場的市場佔有率分析：按最終用戶分類
    • 醫院
    • 專科眼科診所
    • 門診手術中心
    • 研究和學術機構
    • 居家醫療環境

第12章：刺繡市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他中東和非洲國家

第13章：主要供應商分析：Choroideria Industries

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • MeiraGTx Limited（UK）
    • REGENXBIO（US）
    • GenSight Biologics（France）
    • Editas Medicine（US）
    • Spark Therapeutics（US）
    • Sangamo Therapeutics（US）
    • CRISPR Therapeutics AG（Switzerland）
    • Nanoscope Therapeutics, Inc.（US）
    • 4D Molecular Therapeutics（US）
    • ProQR Therapeutics NV（Netherlands）
    • Horama SA（France）
    • Homology Medicines, Inc.（US）
    • Beacon Therapeutics（US）
    • Eyevensys（Switzerland）
    • Visgenx（US）
    • Atsena Therapeutics Inc.（US）
    • Coave Therapeutics（US）
    • Neurophth Therapeutics（China）
    • Johnson & Johnson Services, Inc.（US）
    • Ocugen, Inc.（US）

第14章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV6267

Choroideremia Market size was valued at US$ 9,785.95 Million in 2025, expanding at a CAGR of 4.87% from 2026 to 2033.

Choroideremia is a rare inherited eye disease that mainly affects males and slowly causes vision loss. It starts with difficulty seeing in the dark and gradually leads to loss of side vision and eventually central vision, sometimes resulting in blindness. It mainly affects males. According to government data from the U.S. National Institutes of Health, it affects about 1 in 50,000 to 100,000 people and contributes to a portion of blindness cases. The choroideremia market is the business around making and selling treatments for this rare eye disease, especially newer options like gene therapy. Even though very few people have it, the market is still expanding because companies are investing more in research, new treatment methods are being developed, and there is a clear need for treatments that can actually slow down or stop vision loss over time.

Choroideremia Market- Market Dynamics

Increasing Emphasis on Gene Therapy Development

A key factor driving the choroideremia market is the increasing development of gene therapy, backed by government support and regulatory incentives. The National Institutes of Health promotes gene therapy programs for rare diseases through funding and initiatives, as these conditions often have limited treatment options. Since choroideremia is caused by a single gene mutation, it is well suited for gene replacement approaches, and government-supported studies have already pushed these therapies into clinical trials with visible patient benefits. Companies like Biogen Inc., Spark Therapeutics, and REGENXBIO Inc. are actively working on such treatments. In addition, the U.S. Food and Drug Administration offers orphan drug and rare disease designations, helping companies move faster, which directly increases research activity and market growth.

Choroideremia Market- Segmentation Analysis:

The Global Choroideremia Market is segmented on the basis of Treatment Type, Route of Administration, Patient Demographics, Disease Stage, End User, and Region.

The market is split into six segments according to treatment type: Gene Therapy, Surgical Intervention, Pharmacological Treatment, Symptomatic Treatment, Cell Therapy, and Drug Therapy. Gene therapy is the most important part of this market because it directly fixes the main cause of the disease, the damaged CHM gene, while other options, like drugs or surgery, only manage symptoms and cannot stop vision loss. This disease is very rare, affecting roughly 1 in 50,000 to 100,000 people, which is why governments classify it under rare diseases and support development through orphan drug programs and research funding. Gene therapy stands out because it uses viral vectors (like AAV) to deliver a working gene into retinal cells, and clinical trials have already shown maintained or improved vision in some patients. Because it offers a one-time treatment approach, targets the root problem, and shows real clinical results, most funding, trials, and regulatory attention are focused on gene therapy, making it the most widely adopted segment.

The market is structured into four segments in terms of Route of Administration: Subretinal Injection, Intravitreal Injection, Oral Route, and Intravenous Route. The subretinal injection is anticipated to play a central role in the choroideremia market because it delivers gene therapy directly to the damaged retinal cells where the disease occurs. Government-supported clinical research shows that gene therapies for choroideremia are primarily administered through subretinal delivery, as seen in trials using AAV-based treatments that directly target the retinal pigment epithelium and photoreceptors. Scientific studies also confirm that subretinal injection provides more precise and effective delivery compared to other routes, ensuring higher drug concentration at the target site. This approach is widely used by companies such as Spark Therapeutics and REGENXBIO Inc., which focus on AAV-based therapies requiring direct retinal delivery. Key features of this segment include targeted gene transfer, improved treatment effectiveness, and suitability for one-time therapy, which makes it the most widely adopted route despite being more invasive than alternatives like intravitreal injection.

Choroideremia Market- Geographical Insights

North America is forecasted to register meaningful growth of the choroideremia market due to its strong research base and consistent government support for rare disease therapies. The National Institutes of Health funds multiple gene therapy programs for inherited retinal diseases, supporting both early-stage and clinical research, while the U.S. Food and Drug Administration provides orphan drug designations that help speed up treatment development. Government-backed studies in the U.S. have already advanced gene therapy for choroideremia into human trials with measurable vision improvements, supported by companies such as Spark Therapeutics and REGENXBIO Inc. Europe represents the next significant region, supported by active clinical research and public healthcare involvement, where government-backed trials in the United Kingdom, including funding from the UK Department of Health, have contributed to early human studies of subretinal gene therapy, along with structured rare disease policies that support ongoing research and patient access.

Canada Choroideremia Market- Country Insights

Canada represents an important country in the choroideremia market due to steady government-supported research and a clear healthcare focus on rare eye diseases. According to data supported by organizations like Fighting Blindness Canada, around 21,000 Canadians are living with inherited retinal diseases, including choroideremia, showing a defined patient base that requires long-term care and treatment. In addition, government-linked clinical studies in Canada highlight that over 68% of patients with these conditions are legally blind, indicating a serious healthcare burden and the need for effective therapies. The country also has strong academic and clinical involvement, with institutions such as the University of Alberta contributing to genetic research and the diagnosis of choroideremia. Companies and research groups working with gene-based approaches are supported through public healthcare systems and collaborations with global biotech firms. Overall, Canada's structured healthcare system, ongoing research efforts, and clearly identified patient population support continued development and adoption of new treatments in a stable and organized manner.

Choroideremia Market- Competitive Landscape:

The competitive landscape of the choroideremia market is shaped by a group of biotechnology and pharmaceutical companies focusing on gene-based treatments, as there are limited approved options and ongoing clinical development. Key players include Biogen Inc., Spark Therapeutics, REGENXBIO Inc., MeiraGTx Holdings plc, and 4D Molecular Therapeutics, all working on AAV-based gene therapies targeting the underlying genetic cause. Government-supported clinical data show that multiple gene therapy trials for choroideremia have already progressed to Phase I, II, and III stages across the U.S., UK, and other regions, indicating steady development activity. In addition, public research funding from institutions such as the National Institute for Health and Care Research in the UK and similar government bodies supports clinical studies and infrastructure for these trials. The market remains research-driven, with companies focusing on clinical trial advancement, regulatory approvals, and long-term treatment outcomes, as gene therapy continues to be the primary area of development.

Recent Developments:

In October 2025, DelveInsight and other industry pipeline insights highlighted expanding clinical research and multi-modal approaches (gene therapy, gene editing, RNA-based therapies, optogenetics) advancing through preclinical and clinical stages for choroideremia, signaling broadening therapeutic research activity. This trend reflects a gradual shift toward more diverse treatment strategies, with multiple technologies being explored to address the disease from different angles, indicating steady progress in development efforts and a wider scope for future therapeutic options.

In June 2025, the Choroideremia Research Foundation awarded six new global research grants to accelerate vision science and treatment innovation in choroideremia, funding projects including CRISPR-based gene editing and long-term gene therapy follow-up studies. This reflects continued financial and scientific support for advanced research approaches, with a clear focus on improving long-term treatment outcomes and expanding the scope of therapeutic development for the condition.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHOROIDEREMIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • MeiraGTx Limited (U.K.)
  • REGENXBIO (U.S.)
  • GenSight Biologics (France)
  • Editas Medicine (U.S.)
  • Spark Therapeutics (U.S.)
  • Sangamo Therapeutics (U.S.)
  • CRISPR Therapeutics AG (Switzerland)
  • Nanoscope Therapeutics, Inc. (U.S.)
  • 4D Molecular Therapeutics (U.S.)
  • ProQR Therapeutics N.V. (Netherlands)
  • Horama SA (France)
  • Homology Medicines, Inc. (U.S.)
  • Beacon Therapeutics (U.S.)
  • Eyevensys (Switzerland)
  • Visgenx (U.S.)
  • Atsena Therapeutics Inc. (U.S.)
  • Coave Therapeutics (U.S.)
  • Neurophth Therapeutics (China)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Ocugen, Inc. (U.S.)

GLOBAL CHOROIDEREMIA MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020 - 2033

  • Gene Therapy
  • Surgical Intervention
  • Pharmacological Treatment
  • Symptomatic Treatment
  • Cell Therapy
  • Drug Therapy

GLOBAL CHOROIDEREMIA MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Subretinal Injection
  • Intravitreal Injection
  • Oral Route
  • Intravenous Route

GLOBAL CHOROIDEREMIA MARKET, BY PATIENT DEMOGRAPHICS- MARKET ANALYSIS, 2020 - 2033

  • Pediatric Patients
  • Adult Patients
  • Geriatric Patients

GLOBAL CHOROIDEREMIA MARKET, BY DISEASE STAGE- MARKET ANALYSIS, 2020 - 2033

  • Early Stage
  • Mid Stage
  • Late Stage

GLOBAL CHOROIDEREMIA MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Hospitals
  • Specialty Ophthalmology Clinics
  • Ambulatory Surgical Centers
  • Research & Academic Institutes
  • Homecare Settings

GLOBAL CHOROIDEREMIA MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Choroideremia Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Choroideremia Market Snippet by Treatment Type
    • 2.1.2. Choroideremia Market Snippet by Route of Administration
    • 2.1.3. Choroideremia Market Snippet by Patient Demographics
    • 2.1.4. Choroideremia Market Snippet by Disease Stage
    • 2.1.5. Choroideremia Market Snippet by End User
    • 2.1.6. Choroideremia Market Snippet by Country
    • 2.1.7. Choroideremia Market Snippet by Region
  • 2.2. Competitive Insights

3. Choroideremia Key Market Trends

  • 3.1. Choroideremia Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Choroideremia Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Choroideremia Market Opportunities
  • 3.4. Choroideremia Market Future Trends

4. Choroideremia Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Choroideremia Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Choroideremia Market Landscape

  • 6.1. Choroideremia Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Choroideremia Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
    • 7.1.2. Gene Therapy
    • 7.1.3. Surgical Intervention
    • 7.1.4. Pharmacological Treatment
    • 7.1.5. Symptomatic Treatment
    • 7.1.6. Cell Therapy
    • 7.1.7. Drug Therapy

8. Choroideremia Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 8.1.2. Subretinal Injection
    • 8.1.3. Intravitreal Injection
    • 8.1.4. Oral Route
    • 8.1.5. Intravenous Route

9. Choroideremia Market - By Patient Demographics

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Patient Demographics, 2025 & 2033 (%)
    • 9.1.2. Pediatric Patients
    • 9.1.3. Adult Patients
    • 9.1.4. Geriatric Patients

10. Choroideremia Market - By Disease Stage

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 10.1.2. Early Stage
    • 10.1.3. Mid Stage
    • 10.1.4. Late Stage

11. Choroideremia Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
    • 11.1.2. Hospitals
    • 11.1.3. Specialty Ophthalmology Clinics
    • 11.1.4. Ambulatory Surgical Centers
    • 11.1.5. Research & Academic Institutes
    • 11.1.6. Homecare Settings

12. Choroideremia Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Choroideremia Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Choroideremia Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Choroideremia Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Choroideremia Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Choroideremia Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

13. Key Vendor Analysis- Choroideremia Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. MeiraGTx Limited (U.K.)
    • 13.2.2. REGENXBIO (U.S.)
    • 13.2.3. GenSight Biologics (France)
    • 13.2.4. Editas Medicine (U.S.)
    • 13.2.5. Spark Therapeutics (U.S.)
    • 13.2.6. Sangamo Therapeutics (U.S.)
    • 13.2.7. CRISPR Therapeutics AG (Switzerland)
    • 13.2.8. Nanoscope Therapeutics, Inc. (U.S.)
    • 13.2.9. 4D Molecular Therapeutics (U.S.)
    • 13.2.10. ProQR Therapeutics N.V. (Netherlands)
    • 13.2.11. Horama SA (France)
    • 13.2.12. Homology Medicines, Inc. (U.S.)
    • 13.2.13. Beacon Therapeutics (U.S.)
    • 13.2.14. Eyevensys (Switzerland)
    • 13.2.15. Visgenx (U.S.)
    • 13.2.16. Atsena Therapeutics Inc. (U.S.)
    • 13.2.17. Coave Therapeutics (U.S.)
    • 13.2.18. Neurophth Therapeutics (China)
    • 13.2.19. Johnson & Johnson Services, Inc. (U.S.)
    • 13.2.20. Ocugen, Inc. (U.S.)

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us